A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer
暂无分享,去创建一个
Jason T. George | R. Schiff | C. Creighton | H. Levine | Fengju Chen | C. Osborne | M. Jolly | S. Vasaikar | Bing Zhang | C. Nagi | M. Lewis | C. Angelis | M. Rimawi | L. Dobrolecki | Sufeng Mao | M. Giuliano | Hariprasad Thangavel | M. Trivedi | A. Nardone | R. Bhat | T. Kumar | N. Abdulkareem | Agostina Nardone | Raksha R Bhat | Meghana V. Trivedi | M. Lewis | Tanya Kumar
[1] D. Santini,et al. A simple immunohistochemical bio-profile incorporating Bcl2 curbs those cases of invasive breast carcinoma for which an Oncotype Dx characterization is needed , 2019, PloS one.
[2] Chun-chun Xue,et al. The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis , 2019, Front. Oncol..
[3] R. Schiff,et al. Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis , 2019, BMC Cancer.
[4] Yang Shen,et al. Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. , 2018, Cancer discovery.
[5] F. Garcia,et al. BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score , 2018, BMC Clinical Pathology.
[6] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[7] Guang-lei Qiao,et al. Prognostic value of CD44v6 expression in breast cancer: a meta-analysis , 2018, OncoTargets and therapy.
[8] N. Loman,et al. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial , 2018, Breast Cancer Research.
[9] M. Harada,et al. Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin , 2018, Oncotarget.
[10] C. Chen,et al. The biology and role of CD44 in cancer progression: therapeutic implications , 2018, Journal of Hematology & Oncology.
[11] K. Hirakawa,et al. Correction to: Circulating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer , 2017, Biomarker Research.
[12] R. Schiff,et al. Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. , 2018, Cancer research.
[13] Ryan Miller,et al. WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research , 2017, Nucleic Acids Res..
[14] Sohee Oh,et al. BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database , 2017, Cancer research and treatment : official journal of Korean Cancer Association.
[15] L. D. White,et al. EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells , 2017, Nature Communications.
[16] K. Xie,et al. The Role of CD44 and Cancer Stem Cells. , 2018, Methods in molecular biology.
[17] Ž. Vujašković,et al. Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients , 2018, The International journal of biological markers.
[18] Marilyn M. Li,et al. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer , 2018, Breast Cancer Research and Treatment.
[19] T. Graeber,et al. Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer , 2018, Annals of Surgical Oncology.
[20] Mohit Kumar Jolly,et al. Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric. , 2017, Cancer research.
[21] Chen Wang,et al. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis , 2017, Scientific Reports.
[22] W. El-Deiry,et al. Circulating tumor cells: silent predictors of metastasis , 2017, F1000Research.
[23] Luana Mota Martins,et al. Bcl-2 antigen expression in luminal A and triple-negative breast cancer , 2017, Medical Oncology.
[24] S. Tomita,et al. Circulating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer , 2017, Biomarker Research.
[25] Jing Wang,et al. WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit , 2017, Nucleic Acids Res..
[26] D. Ding,et al. The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis , 2017, Cancer Cell International.
[27] Yan-ping Wang,et al. Prognostic Significance of CD24 and CD44 in Breast Cancer: A Meta-Analysis , 2017, The International journal of biological markers.
[28] François Vaillant,et al. Patient-derived xenograft (PDX) models in basic and translational breast cancer research , 2016, Cancer and Metastasis Reviews.
[29] Qi Zhang,et al. Circulating tumor cell clusters: What we know and what we expect (Review) , 2016, International journal of oncology.
[30] A. Lánczky,et al. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients , 2016, Breast Cancer Research and Treatment.
[31] Hushan Yang,et al. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer , 2016, International journal of molecular sciences.
[32] J. Hanaoka,et al. Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors , 2016, ESMO Open.
[33] P. Bendahl,et al. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort , 2016, BMC Cancer.
[34] Pu Xia,et al. Prognostic significance of CD44 in human colon cancer and gastric cancer: Evidence from bioinformatic analyses , 2016, Oncotarget.
[35] Jaime Rodriguez-Canales,et al. Image Analysis–based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non–small Cell Lung Carcinoma Patients , 2016, Clinical Cancer Research.
[36] G. Wilson,et al. The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer , 2016, Stem cells international.
[37] E. Ben-Jacob,et al. Stability of the hybrid epithelial/mesenchymal phenotype , 2016, Oncotarget.
[38] Gen Sheng Wu,et al. Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis , 2016, OncoTargets and therapy.
[39] Hushan Yang,et al. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer , 2016, Breast Cancer Research and Treatment.
[40] Hushan Yang,et al. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer , 2015, Breast Cancer Research and Treatment.
[41] F. Akiyama,et al. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy , 2015, BMC Cancer.
[42] M. Daidone,et al. Did Circulating Tumor Cells Tell us all they Could? The Missed Circulating Tumor Cell Message in Breast Cancer , 2015, The International journal of biological markers.
[43] Eshel Ben-Jacob,et al. Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis , 2015, Front. Oncol..
[44] Y. Miyagi,et al. Establishment of patient-derived cancer xenografts in immunodeficient NOG mice , 2015, International journal of oncology.
[45] Sridhar Ramaswamy,et al. A microfluidic device for label-free, physical capture of circulating tumor cell-clusters , 2015, Nature Methods.
[46] J. Visvader,et al. Patient-derived xenograft models of breast cancer and their predictive power , 2015, Breast Cancer Research.
[47] L. Radová,et al. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy , 2015, Tumor Biology.
[48] C. Shaw,et al. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis , 2015, Breast Cancer Research.
[49] Sridhar Ramaswamy,et al. Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis , 2014, Cell.
[50] Prahlad T. Ram,et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas , 2014, Nature Communications.
[51] Caroline Dive,et al. Molecular analysis of circulating tumour cells—biology and biomarkers , 2014, Nature Reviews Clinical Oncology.
[52] D. Beebe,et al. Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker. , 2014, Journal of patient-centered research and reviews.
[53] G. Ball,et al. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[54] Chad A Shaw,et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. , 2013, Cancer research.
[55] Matthew E. Ritchie,et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. , 2013, Cancer cell.
[56] Klaus Pantel,et al. Circulating tumor cells: liquid biopsy of cancer. , 2013, Clinical chemistry.
[57] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[58] F. Hirsch,et al. Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[59] Peter Kuhn,et al. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors , 2012, Physical biology.
[60] G. Hortobagyi,et al. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer , 2012, International Journal of Clinical Oncology.
[61] Zoltan Szallasi,et al. Jetset: selecting the optimal microarray probe set to represent a gene , 2011, BMC Bioinformatics.
[62] Mark T. W. Ebbert,et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.
[63] O. Sansom,et al. HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer , 2011, Proceedings of the National Academy of Sciences.
[64] Matthew E. Ritchie,et al. Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737 , 2011, Proceedings of the National Academy of Sciences.
[65] Massimo Cristofanilli,et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment , 2011, Breast Cancer Research.
[66] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[67] Caroline Dive,et al. Circulating tumor cells as a window on metastasis biology in lung cancer. , 2011, The American journal of pathology.
[68] Shu Ichihara,et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists , 2011, Modern Pathology.
[69] M. Tsao,et al. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors , 2009, Oncogene.
[70] Kristine Broglio,et al. Circulating tumor cells in metastatic breast cancer , 2008, Cancer.
[71] A. Gennari. The Impact of New Chemotherapeutic and Hormone Agents on Survival in a Population-based Cohort of Women with Metastatic Breast Cancer , 2008 .
[72] K. Gelmon,et al. The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancer , 2007, Cancer.
[73] Leon W.M.M. Terstappen,et al. Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer , 2006, Clinical Cancer Research.
[74] C. Orlandini,et al. Survival of metastatic breast carcinoma patients over a 20‐year period , 2005, Cancer.
[75] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[76] Alison Stopeck,et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.
[77] Chan Zeng,et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[79] M. Ruggiero,et al. Role of three cancer "master genes" p53, bcl2 and c-myc on the apoptotic process. , 1996, Tumori.
[80] P. Nowell,et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.